Literature DB >> 23446557

Predisposing factors for primary acquired nasolacrimal duct obstruction.

Kazuyoshi Ohtomo1, Takashi Ueta, Taku Toyama, Miyuki Nagahara.   

Abstract

BACKGROUND: Pathological origin of primary acquired nasolacrimal duct obstruction (PANDO) is considered as inflammation of unknown causes; however, specific predisposing factors have not been fully addressed to date.
METHODS: In an institutional setting, background factors of 45 patients with PANDO were compared to those in 67 control subjects. The control subjects were persons with senile cataract, representing the non-pathological general population. The evaluated background factors were inflammatory medical histories (infectious conjunctivitis and allergic conjunctivitis and/or rhinitis), previously reported factors (POAG and topical timolol), and a novel factor proposed in the current study (exposure to swimming pool). Data were extracted from the patients through interview based on a standardized questionnaire as well as from their clinical records.
RESULTS: After adjustment for age and gender, a history of infectious conjunctivitis was more common in the PANDO group than in the control group (55.6 % vs 32.8 %, P = 0.0027), and regular attendance to indoor swimming pools was also more common in the PANDO group (33.3 % vs 0 %, P < 0.0001). Furthermore, when age- and gender- matched subjects were selected, a history of conjunctivitis and swimming pool exposure were independently associated with the development of PANDO (P = 0.022 and P < 0.0001 respectively). On the other hand, the frequencies of histories of POAG, topical timolol, and allergic conjunctivitis and/or rhinitis were similar between the two groups.
CONCLUSIONS: Histories of infectious conjunctivitis and swimming pool exposure could be associated with the development of PANDO, although the pathogenesis of this condition has been considered as inflammation of unknown causes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446557     DOI: 10.1007/s00417-013-2288-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  12 in total

Review 1.  Acquired lacrimal drainage obstruction: an etiologic classification system, case reports, and a review of the literature. Part 1.

Authors:  G B Bartley
Journal:  Ophthalmic Plast Reconstr Surg       Date:  1992       Impact factor: 1.746

2.  Epiphora: the role of rhinitis.

Authors:  H Kubba; A K Robson; M A Bearn
Journal:  Am J Rhinol       Date:  1998 Jul-Aug

3.  Clinicopathologic analysis of 166 patients with primary acquired nasolacrimal duct obstruction.

Authors:  M W Lee-Wing; M E Ashenhurst
Journal:  Ophthalmology       Date:  2001-11       Impact factor: 12.079

4.  Allergic nasolacrimal obstruction. Case report.

Authors:  D M Reifler
Journal:  Arch Ophthalmol       Date:  1988-02

5.  Primary acquired nasolacrimal duct obstruction. A clinicopathologic report and biopsy technique.

Authors:  J V Linberg; S A McCormick
Journal:  Ophthalmology       Date:  1986-08       Impact factor: 12.079

6.  Longitudinal monitoring of lung injury in children after acute chlorine exposure in a swimming pool.

Authors:  Gea Bonetto; Massimo Corradi; Silvia Carraro; Stefania Zanconato; Rossella Alinovi; Giuseppina Folesani; Liviana Da Dalt; Antonio Mutti; Eugenio Baraldi
Journal:  Am J Respir Crit Care Med       Date:  2006-06-08       Impact factor: 21.405

7.  Exposure to trichloramine and respiratory symptoms in indoor swimming pool workers.

Authors:  J H Jacobs; S Spaan; G B G J van Rooy; C Meliefste; V A C Zaat; J M Rooyackers; D Heederik
Journal:  Eur Respir J       Date:  2006-11-15       Impact factor: 16.671

8.  Diameter of the bony lacrimal canal: normal values and values related to nasolacrimal duct obstruction: assessment with CT.

Authors:  A G Janssen; K Mansour; J J Bos; J A Castelijns
Journal:  AJNR Am J Neuroradiol       Date:  2001-05       Impact factor: 3.825

9.  Pseudonasolacrimal duct obstruction caused by nasal allergy.

Authors:  R F Sanke
Journal:  Ophthalmic Surg       Date:  1989-01

10.  Not only training but also exposure to chlorinated compounds generates a response to oxidative stimuli in swimmers.

Authors:  Raphaëlle Varraso; Nicole Massin; Michel Hery; Martine Fradier-Dusch; Jean-Pierre Michaely; Maryvonne Fournier; Geneviève Hubert; Patrick Biette; Benoit Rieger; Aline Berthelin; Gerard Hecht; Rachel Nadif
Journal:  Toxicol Ind Health       Date:  2002-07       Impact factor: 2.273

View more
  5 in total

1.  Primary acquired nasolacrimal duct obstruction: is it really related to paranasal abnormalities?

Authors:  Hasmet Yazici; Erdogan Bulbul; Alper Yazici; Mustafa Kaymakci; Nesime Tiskaoglu; Bahar Yanik; Samet Ermis
Journal:  Surg Radiol Anat       Date:  2014-11-25       Impact factor: 1.246

2.  Avoiding dacryocystorhinostomy in cases of epiphora caused by inferior meatus obstruction.

Authors:  Dvir Koenigstein; Ran Ben Cnaan; Shay Keren; Igal Leibovitch; Ahmad Safadi; Roee Landsberg; Avraham Abergel
Journal:  Eye (Lond)       Date:  2018-05-18       Impact factor: 3.775

3.  Sinonasal Anatomical Variations and Primary Acquired Nasolacrimal Duct Obstruction: A Single Centre, Case-Control Investigation.

Authors:  Reza Samarei; Vafa Samarei; Naser Samadi Aidenloo; Nasrin Fateh
Journal:  Eurasian J Med       Date:  2020-02

4.  Morphometric Evaluation of Bony Nasolacrimal Canal in a Caucasian Population with Primary Acquired Nasolacrimal Duct Obstruction: A Multidetector Computed Tomography Study.

Authors:  Erdogan Bulbul; Alper Yazici; Bahar Yanik; Hasmet Yazici; Gulen Demirpolat
Journal:  Korean J Radiol       Date:  2016-03-02       Impact factor: 3.500

5.  Combined Lacrimal Passage Probing and Tobramycin/Dexamethasone Ophthalmic Ointment Infiltration: A Minimally Invasive Surgical Procedure for Incomplete Nasolacrimal Duct Obstruction.

Authors:  Jianjiang Xu; Jiaxu Hong; Xinghuai Sun; Zuguo Liu; Alireza Mashaghi; Takenori Inomata; Yi Lu; Yimin Li; Dan Wu; Yujing Yang; Anji Wei; Yujin Zhao; Chun Lu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.